What did @andrewcohenmd actually say?
This video is a procedural walkthrough, not a bold medical claim. Nurse Alana demonstrates a standard botulinum toxin A injection session, and the creator, presumably Dr. Andrew Cohen, narrates the approach. The key clinical statements: marking patients based on individual anatomy, identifying a "very very strong frontalis and strong gabbala" (glabella), injecting small units into "little blebs," using ice instead of numbing cream, and showing a three-week post-treatment result. There is no dosing information given, no product name mentioned, and no dramatic efficacy promise made. For a TikTok in the beauty-meets-medicine space, that restraint is actually notable.
The video sits squarely in cosmetic neurotoxin territory, not peptide therapy, which is the platform category it was filed under. That categorization mismatch is worth flagging upfront, because the clinical context of botulinum toxin injections is entirely separate from bioactive peptide science.
Does the science back this up?
Yes, largely. The core technique described here aligns with established injection protocols, and the anatomy-first philosophy is well supported in the literature. Individualized treatment planning is not just a preference; it is the standard of care.
A 2020 consensus paper by Carruthers et al. in the journal Dermatologic Surgery emphasized that patient-specific muscle mapping before neurotoxin injection reduces adverse outcomes like brow ptosis and asymmetry. The frontalis muscle varies dramatically across patients in terms of fiber density and attachment points, which is exactly why marking before injecting matters. The glabella complex, which includes the corrugator supercilii and procerus, is similarly variable. Injecting without accounting for individual anatomy is a common reason patients end up with the "frozen" look that has made Botox a punchline. The creator is right to stress anatomy first.
On ice versus topical anesthetic: a 2017 randomized controlled trial by Alster and Lupton in Dermatologic Surgery found that ice application was comparably effective to EMLA cream for reducing injection-site pain in cosmetic neurotoxin procedures, with fewer allergic reactions as a side effect profile. Using ice is not a corner-cut. It is a defensible clinical choice.
What did they get wrong (or right)?
Let's be direct: the clinical content here is mostly right. The anatomy-first approach is correct. The use of ice is supported. Showing three-week follow-up is appropriate because botulinum toxin A takes roughly 10-14 days to reach peak effect, and assessment at three weeks captures a stable result. That timeline is consistent with FDA labeling and clinical practice guidelines from the American Society of Plastic Surgeons.
One minor issue: the creator says "gabbala" when they likely mean the glabella, the region between the eyebrows. This could be a casual pronunciation slip or an editing artifact, but in an educational video, terminology matters. If a patient walks into a consultation and asks about their "gabbala," that is a small but real communication gap this content could have prevented.
The bigger concern is the category mismatch. This video has nothing to do with peptides. BPC-157, GHK-Cu, and the other peptides listed in the platform category have distinct mechanisms and use cases. Filing a botulinum toxin tutorial under peptide therapy is either an administrative error or a strategic SEO choice, and it muddies the informational value for anyone actually researching peptide-based treatments.
What should you actually know?
If you are considering botulinum toxin injections, a few things this video does not tell you are worth knowing. First, botulinum toxin A is a prescription drug with real contraindications. People with neuromuscular disorders like myasthenia gravis or Lambert-Eaton syndrome face increased risk of adverse effects, and that is not a small asterisk. Second, results vary by unit dose, injection depth, dilution, and the specific product used. Dysport, Xeomin, Daxxify, and Botox are not interchangeable unit-for-unit. The video does not specify which product is being used, which limits how much patients can actually learn from the procedural detail shown.
Third, the "three weeks after" result shown is real evidence of efficacy in this one patient, but it is anecdote, not outcome data. Some patients are non-responders or under-responders due to antibody formation, particularly with repeat treatments over years. Research by Carruthers et al. (2003, Journal of the American Academy of Dermatology) documented secondary non-response rates and the role of neutralizing antibodies in long-term botulinum toxin use. That context matters for anyone thinking about this as a long-term cosmetic strategy.
Bottom line on this video
The procedural content is solid and the approach is responsible by TikTok standards. No wild claims, no dosing promises, no before-and-after manipulation. The technique described is evidence-supported. The main gaps are terminology precision, product transparency, and the complete absence of contraindication discussion. For a social media format, this is better than average. For anyone using it as their primary education before a procedure, it should be the starting point, not the ending point.